» Articles » PMID: 27339708

The Role of Myeloid Cells in Cancer Therapies

Overview
Journal Nat Rev Cancer
Specialty Oncology
Date 2016 Jun 25
PMID 27339708
Citations 438
Authors
Affiliations
Soon will be listed here.
Abstract

Recent clinical trials have demonstrated the ability to durably control cancer in some patients by manipulating T lymphocytes. These immunotherapies are revolutionizing cancer treatment but benefit only a minority of patients. It is thus a crucial time for clinicians, cancer scientists and immunologists to determine the next steps in shifting cancer treatment towards better cancer control. This Review describes recent advances in our understanding of tumour-associated myeloid cells. These cells remain less studied than T lymphocytes but have attracted particular attention because their presence in tumours is often linked to altered patient survival. Also, experimental studies indicate that myeloid cells modulate key cancer-associated activities, including immune evasion, and affect virtually all types of cancer therapy. Consequently, targeting myeloid cells could overcome limitations of current treatment options.

Citing Articles

Myeloid cells: key players in tumor microenvironments.

Hua Q, Li Z, Weng Y, Wu Y, Zheng L Front Med. 2025; .

PMID: 40048137 DOI: 10.1007/s11684-025-1124-8.


Pan‑immune‑inflammatory values predict survival in patients after radical surgery for non‑metastatic colorectal cancer: A retrospective study.

Li K, Zeng X, Zhang Z, Wang K, Pan Y, Wu Z Oncol Lett. 2025; 29(4):197.

PMID: 40046636 PMC: 11880885. DOI: 10.3892/ol.2025.14943.


Thymidine kinase 1 indicates resistance to immune checkpoint plus tyrosine kinase inhibition in renal cell carcinoma.

Wang J, Xu X, Wang Y, Zhu Y Cell Oncol (Dordr). 2025; .

PMID: 40009128 DOI: 10.1007/s13402-025-01048-7.


Scupa: single-cell unified polarization assessment of immune cells using the single-cell foundation model.

Liu W, Zhao Z Bioinformatics. 2025; 41(3).

PMID: 39999031 PMC: 11893155. DOI: 10.1093/bioinformatics/btaf090.


Thiostrepton suppresses intrahepatic cholangiocarcinoma progression via FOXM1-mediated tumor-associated macrophages reprogramming.

Li Y, Jiang Y, Tong R, Ding B, Ge J, Du K Transl Oncol. 2025; 54:102327.

PMID: 39986191 PMC: 11904789. DOI: 10.1016/j.tranon.2025.102327.


References
1.
Dieu-Nosjean M, Antoine M, Danel C, Heudes D, Wislez M, Poulot V . Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. 2008; 26(27):4410-7. DOI: 10.1200/JCO.2007.15.0284. View

2.
Pittet M, Nahrendorf M, Swirski F . The journey from stem cell to macrophage. Ann N Y Acad Sci. 2014; 1319:1-18. PMC: 4074243. DOI: 10.1111/nyas.12393. View

3.
Pan P, Ma G, Weber K, Ozao-Choy J, Wang G, Yin B . Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res. 2009; 70(1):99-108. PMC: 2805053. DOI: 10.1158/0008-5472.CAN-09-1882. View

4.
Hubo M, Trinschek B, Kryczanowsky F, Tuettenberg A, Steinbrink K, Jonuleit H . Costimulatory molecules on immunogenic versus tolerogenic human dendritic cells. Front Immunol. 2013; 4:82. PMC: 3615188. DOI: 10.3389/fimmu.2013.00082. View

5.
Strachan D, Ruffell B, Oei Y, Bissell M, Coussens L, Pryer N . CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8 T cells. Oncoimmunology. 2014; 2(12):e26968. PMC: 3902121. DOI: 10.4161/onci.26968. View